OHRP Ohr Pharmaceuticals, Inc.

0.73
0  -2%
Previous Close 0.75
Open 0.73
Price To book 1.04
Market Cap 26.40M
Shares 35,961,000
Volume 170,415
Short Ratio 2.13
Av. Daily Volume 355,487

SEC filingsSee all SEC filings

  1. 8-K - Current report 17770487
  2. 8-K - Current report 17754264
  3. 8-K - Current report 17746096
  4. 424B5 - Prospectus (Rule 424(b)(5)) 17746066
  5. 424B5 - Prospectus (Rule 424(b)(5)) 17739571

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due late 2017 or early 2018.
OHR-102
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase 2 data released July 2015
OHR-102
Retinal vein occlusion (CRVO)

Latest News

  1. Ohr Pharmaceutical (OHRP) Jumps: Stock Adds 15% in Session
  2. Ohr Pharmaceutical Provides Update on Squalamine Study
  3. Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD
  4. Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants
  5. Ohr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants
  6. Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants
  7. Ohr Pharmaceutical to Present at the Cowen & Company 37th Annual Health Care Conference
  8. The Market Has Got Its Interpretation Of The OHR Pharmaceutical Inc (OHRP) Announcement Wrong
  9. Ohr Pharmaceutical Reports 4Q Loss, Suspends Trial
  10. Ohr Pharmaceutical Announces Strategic Update and Fiscal First Quarter 2017 Earnings
  11. Ohr Pharmaceutical to Announce First Quarter 2017 Financial Results on February 14
  12. Post Earnings Coverage as Ohr Pharma Reported Annual Results; Announced Closure of Public Offering
  13. Ohr Pharmaceutical, Inc. :OHRP-US: Earnings Analysis: Q4, 2016 By the Numbers : December 27, 2016
  14. Which Wet AMD Stock Would You Buy Right Now?
  15. What Fovista's Fail Means For OHR Pharma
  16. Ohr Pharmaceuticals Expects $8M from Public Offering
  17. Ohr Pharma Drops on Secondary Offering

SEC Filings

  1. 8-K - Current report 17770487
  2. 8-K - Current report 17754264
  3. 8-K - Current report 17746096
  4. 424B5 - Prospectus (Rule 424(b)(5)) 17746066
  5. 424B5 - Prospectus (Rule 424(b)(5)) 17739571
  6. 8-K - Current report 17738886
  7. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17665079
  8. DEF 14A - Other definitive proxy statements 17665038
  9. 8-K - Current report 17629641
  10. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17612605